An Avastin Loophole: Hamburg Could Decide To Retain Approval During Confirmatory Trial

Even if the commissioner determines the grounds for withdrawing Avastin's accelerated approval in breast cancer have been met, she could decide to retain the claim while Genentech conducts additional confirmatory trials, the hearing notice explains.